荧光定量聚合酶链反应检测c-myc在乳腺癌诊断中的临床应用

摘要

目的 建立荧光定量聚合酶链反应(FQ-PCR)法检测核内原癌基因c-myc表达水平,探讨其在乳腺癌诊断和治疗监测中的应用.方法 建立FQ-PCR法,并以β2-微球蛋白作为内对照测定30名健康女性体检者、30例良性乳腺疾病患者和81例乳腺癌患者外周血中c-myc的表达水平.结果 c-myc表达水平在正常对照组和良性乳腺疾病组间差异无统计学意义(P>0.05),乳腺癌组均高于前2组(P<0.05),β2-微球蛋白在3组间差异无统计学意义(P>0.05).81例乳腺癌患者阳性率为40.7%,良性乳腺疾病组为0.c-myc表达水平与患者年龄和肿瘤大小和类型无关(P>0.05),与乳腺癌临床分期、组织学分级以及腋淋巴结转移相关(P<0.05).结论 FQ-PCR技术是高灵敏度、高特异性的快速定量检测c-myc方法,可有效监测乳腺癌的诊断、疗效、转移和预后.%Objective To evaluate the clinical application of fluorescent quantification polymerase chain reaction (FQ-PCR) to detect the expression level of c-myc gene in the diagnosis of breast cancer. Methods The c-myc expression levels in the clinical samples of 30 healthy women, 30 patients with benign breast disease and 81 patients with breast cancer were detected by FQ-PCR. β2-microglobin was used as internal control. Results There was no statistical significance in c-myc expression level between healthy control group and benign breast disease group ( P ＞0.05). The c-myc expression level in breast cancer group was higher than those in the other groups(P ＜0.05). There was no statistical significance in β2-microglobin among the 3 groups ( P ＞ 0.05 ). The positive rates of breast cancer and benign disease groups were 40.7％ and 0 respectively. No significant association of c-myc expression among age, tumor size and tumor type was noted ( P ＞ 0.05 ), but its expression in breast cancer was correlated with clinical stage,histological grade and axillary metastatic lymph node ( P ＜ 0. 05 ). Conclusions FQ-PCR is a rapid, sensitive and specific method for quantitating c-myc gene. It also gives objective evidence to the diagnosis, therapy and metastasis of breast cancer.